Perjeta is used in conjunction with treatments for which type of cancer?

Perjeta, also known by its generic name pertuzumab, is specifically indicated for the treatment of certain types of breast cancer, particularly HER2-positive breast cancer. This medication functions as a targeted therapy that works by inhibiting the HER2 receptor, which is often overexpressed in certain breast cancers and can lead to more aggressive disease. The use of Perjeta is typically in combination with trastuzumab (Herceptin) and docetaxel (a chemotherapy drug) to enhance treatment efficacy.

In contrast, the other types of cancer listed—lung cancer, colorectal cancer, and renal cell carcinoma—do not utilize Perjeta as part of their standard treatment protocols. These cancers have different biological characteristics and require other targeted therapies or chemotherapy agents that are not related to HER2 signaling.